To determine the incidence of clinically significant adverse events after long-term , fixed-dose , generic highly active antiretroviral therapy ( HAART ) use among HIV-infected individuals in South India , we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India .
O O O O O O O O O O O O O O O O O O O O O O O O B-DiseaseOrPhenotypicFeature O O O O O O O O O O O B-DiseaseOrPhenotypicFeature O O O O O O O O O O O O O O O O O O O O O O O O O O O O